# US 2025/0082756 A1 · Muc16 chimeric antigen receptors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0082756 A1
- Document ID: US20250082756A1
- Status: Published application
- Kind: A1
- Application number: 18/727,387
- Filed: 2023-01-10
- Published: 2025-03-13
- Earliest claimed: 2022-01-10
- Assignees: Regeneron Pharmaceuticals, Inc.
- Applicants: Regeneron Pharmaceuticals, Inc.
- Inventors: Tina Albershardt; Geoffrey Blackburn Parsons; David Dilillo
- Web page: https://patentgrep.com/patent/US20250082756A1

## CPC

- A61K 40/4257: {Mucins, e.g. MUC-1}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61P 35/00: Antineoplastic agents
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C07K 14/70517: {CD8}
- C07K 14/70578: {NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95 (NGF-receptor C07K14/71, TNF-receptor C07K14/7151)}
- C07K 16/3092: {against tumour-associated mucins}
- A61K 2239/13: Antibody-based
- A61K 2239/38: characterised by the dose, timing or administration schedule
- A61K 2239/59: Reproductive system, e.g. uterus, ovaries, cervix or testes
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present disclosure provides chimeric antigen receptors (CARs) targeting MUC16, genetically modified immune effector cells, and use of these compositions to treat cancer.

## Claims

### Claim 1

A chimeric antigen receptor (CAR) comprising: an extracellular domain comprising an anti-MUC16 antibody or antigen binding fragment thereof that binds one or more epitopes of a human MUC16 polypeptide; a transmembrane domain, one or more intracellular co-stimulatory signaling domains, and a primary signaling domain.

### Claim 2 (depends on 1)

The CAR of claim 1, wherein the MUC16 antibody or antigen binding fragment thereof binds a membrane proximal fragment of MUC16 remaining on the cell surface after proteolytic cleavage of a full-length MUC16 polypeptide.

### Claim 3 (depends on 2)

The CAR of claim 2, wherein the fragment of MUC16 remaining on the cell surface after proteolytic cleavage comprises SEQ ID NO: 151.

### Claim 4 (depends on 1, 2, 3)

The CAR of any one of claims 1-3, wherein the full-length MUC16 polypeptide comprises 16 sea urchin sperm, enterokinase and agrin (SEA) domains, numbered 1-16 from N-terminus to C-terminus, and wherein the fragment of MUC16 comprises SEA domains 12-16.

### Claim 5 (depends on 1, 2, 3, 4)

The CAR of any one of claims 1-4, wherein the anti-MUC16 antibody or antigen binding fragment that binds the human MUC16 polypeptide is selected from the group consisting of: Fab′ fragment, a F(ab′)2 fragment, a bispecific Fab dimer (Fab2), a trispecific Fab trimer (Fab3), an Fv, an single chain Fv protein (“scFv”), a bis-scFv, (scFv)2, a Camel Ig, a VHH, Ig NAR, a minibody, a diabody, a triabody, a tetrabody, a disulfide stabilized Fv protein (“dsFv”), and a single-domain antibody (sdAb, Nanobody) or fragment thereof.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The CAR of any one of claims 1 to 5, wherein the anti-MUC16 antibody or antigen binding fragment thereof that binds the human MUC16 polypeptide is an scFv.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The CAR of any one of claims 1 to 6, wherein the anti-MUC16 antibody or antigen binding fragment thereof comprises CDRL1, CDRL2, and CDRL3 regions within a variable light chain amino acid sequence as set forth in SEQ ID NO: 7.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6)

The CAR of any one of claims 1 to 6, wherein the anti-MUC16 antibody or antigen binding fragment thereof comprises CDRL1, CDRL2, and CDRL3 regions within a variable light chain amino acid sequence as set forth in any one of SEQ ID NOs: 47, 59, 71, 83, 95, 107, 119, 133, or 145.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The CAR of any one of claims 1 to 8, wherein the anti-MUC16 antibody or antigen binding fragment thereof comprises CDRH1, CDRH2, and CDRH3 regions within a variable heavy chain amino acid sequence as set forth in SEQ ID NO: 8.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The CAR of any one of claims 1 to 8, wherein the anti-MUC16 antibody or antigen binding fragment thereof comprises CDRH1, CDRH2, and CDRH3 regions within a variable heavy chain amino acid sequence as set forth in any one of SEQ ID NOs: 48, 60, 72, 84, 96, 108, 120, 134, or 146.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The CAR of any one of claims 1 to 10, wherein the anti-MUC16 antibody or antigen binding fragment thereof comprises one or more CDRs as set forth in any one of SEQ ID NOs: 1-3.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The CAR of any one of claims 1 to 10, wherein the anti-MUC16 antibody or antigen binding fragment thereof comprises one or more CDRs as set forth in any one of (a) SEQ ID NOs: 41-43, (b) SEQ ID NOs: 53-55, (c) SEQ ID NOs: 65-67, (d) SEQ ID NOs: 77-79, (e) SEQ ID NOs: 89-91, (f) SEQ ID NOs: 101-103, (g) SEQ ID NOs: 113-115, (h) SEQ ID NOs: 127-129, or (i) SEQ ID NOs: 139-141.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The CAR of any one of claims 1 to 12, wherein the anti-MUC16 antibody or antigen binding fragment thereof comprises one or more CDRs as set forth in any one of SEQ ID NOs: 4-6.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The CAR of any one of claims 1 to 12, wherein the anti-MUC16 antibody or antigen binding fragment thereof comprises one or more CDRs as set forth in any one of (a) SEQ ID NOs: 44-46, (b) SEQ ID NOs: 56-58, (c) SEQ ID NOs: 68-70, (d) SEQ ID NOs: 80-82, (e) SEQ ID NOs: 92-94, (f) SEQ ID NOs: 104-106, (g) SEQ ID NOs: 116-118, (h) SEQ ID NOs: 130-132, or (i) SEQ ID NOs: 142-144.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The CAR of any one of claims 1 to 14, wherein the anti-MUC16 antibody or antigen binding fragment thereof comprises a variable light chain amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% identity to, or comprises SEQ ID NO: 7.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The CAR of any one of claims 1 to 14, wherein the anti-MUC16 antibody or antigen binding fragment thereof comprises a variable light chain amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% identity to, or comprises any one of SEQ ID NOs: 47, 59, 71, 83, 95, 107, 119, 133, or 145.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The CAR of any one of claims 1 to 16, wherein the anti-MUC16 antibody or antigen binding fragment thereof comprises a variable heavy chain amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% identity to, or comprises SEQ ID NO: 8.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The CAR of any one of claims 1 to 16, wherein the anti-MUC16 antibody or antigen binding fragment thereof comprises a variable heavy chain amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% identity to, or comprises any one of SEQ ID NOs: 48, 60, 72, 84, 96, 108, 120, 134, or 146.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The CAR of any one of claims 1 to 18, wherein the transmembrane domain is from a polypeptide selected from the group consisting of: alpha, beta or zeta chain of the T-cell receptor, CD3ε, CD3ζ, CD4, CD5, CD8α, CD9, CD 16, CD22, CD27, CD28, CD33, CD3γ, CD45, CD64, CD80, CD86, CD 134, CD137, CD152, CD 154, and PD1.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The CAR of any one of claims 1 to 18, wherein the transmembrane domain is from a polypeptide selected from the group consisting of: CD8α, CD4, CD45, PD1, and CD154.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The CAR of any one of claims 1 to 18, wherein the transmembrane domain is from CD8α.

### Claim 22 (depends on 21)

The CAR of claim 21, wherein the transmembrane domain comprises the sequence of SEQ ID NO: 154.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The CAR of any one of claims 1 to 22, wherein the one or more co-stimulatory signaling domains are from a co-stimulatory molecule selected from the group consisting of: CARD11, CD2, CD7, CD27, CD28, CD30, CD40, CD54 (ICAM), CD83, CD134 (OX40), CD137 (4-1BB), CD150 (SLAMF1), CD152 (CTLA4), CD223 (LAG3), CD270 (HVEM), CD273 (PD-L2), CD274 (PD-L1), CD278 (ICOS), DAP10, LAT, NKD2C SLP76, TRIM, and ZAP70.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The CAR of any one of claims 1 to 22, wherein the one or more co-stimulatory signaling domains are from a co-stimulatory molecule selected from the group consisting of: CD28, CD134, and CD137 (4-1BB).

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The CAR of any one of claims 1 to 22, wherein the one or more co-stimulatory signaling domains is from CD137 (4-1BB).

### Claim 26 (depends on 25)

The CAR of claim 25, wherein the co-stimulatory signaling domain comprises the sequence of SEQ ID NO: 155.

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)

The CAR of any one of claims 1 to 26, wherein the primary signaling domain is from CD3ζ.

### Claim 28 (depends on 27)

The CAR of claim 27, wherein the primary signaling domain comprises the sequence of SEQ ID NO: 156.

### Claim 29 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

The CAR of any one of claims 1 to 28, further comprising a hinge region polypeptide.

### Claim 30 (depends on 29)

The CAR of claim 29, wherein the hinge region polypeptide comprises a hinge region of CD8α.

### Claim 31 (depends on 30)

The CAR of claim 30, wherein the hinge region polypeptide comprises the sequence of SEQ ID NO: 153.

### Claim 32 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

The CAR of any one of claims 1 to 31, further comprising a signal polypeptide.

### Claim 33 (depends on 32)

The CAR of claim 32, wherein the signal polypeptide comprises an IgG1 heavy chain signal polypeptide, granulocyte-macrophage colony stimulating factor receptor 2 (GM-CSFR2) signal polypeptide, Igκ signal polypeptide, or a CD8α signal polypeptide.

### Claim 34 (depends on 33)

The CAR of claim 33, wherein the signal polypeptide comprises a CD8α signal polypeptide.

### Claim 35 (depends on 34)

The CAR of claim 34, wherein the signal polypeptide comprises the sequence of SEQ ID NO: 152.

### Claim 36 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)

The CAR of any one of claims 1 to 35, further comprising a polypeptide linker between the variable heavy chain and variable light chain domains.

### Claim 37 (depends on 36)

The CAR of claim 36, wherein the polypeptide linker between the variable heavy chain and variable light chain domains comprises an amino acid sequence of any one of SEQ ID NOs: 14-25.

### Claim 38 (depends on 37)

The CAR of claim 37, wherein the polypeptide linker between the variable heavy chain and variable light chain domains comprises a 3xG4S amino acid linker as set forth in SEQ ID NO: 24.

### Claim 39 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38)

The CAR of any one of claims 1 to 38, further comprising a polypeptide linker between the transmembrane domain and one or more intracellular co-stimulatory signaling domains.

### Claim 40 (depends on 39)

The CAR of claim 39, wherein the polypeptide linker between the transmembrane domain and one or more intracellular co-stimulatory signaling domains comprises the sequence of LYC.

### Claim 41 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40)

The CAR of any one of claims 1-40, wherein the anti-MUC16 antibody or antigen binding fragment thereof comprises CDRL1, CDRL2, and CDRL3 regions within a variable light chain amino acid sequence as set forth in SEQ ID NO: 7 and CDRH1, CDRH2 and CDRH3 regions within a variable heavy chain amino acid sequence as set forth in SEQ ID NO: 8; the transmembrane domain is from a polypeptide selected from the group consisting of: CD8α, CD4, CD45, PD1, and CD154; the one or more co-stimulatory signaling domains are from a co-stimulatory molecule selected from the group consisting of: CD28, CD134, and CD137 (4-1BB); and the primary signaling domain is from CD3ζ.

### Claim 42 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40)

The CAR of any one of claims 1-40, wherein the anti-MUC16 antibody or antigen binding fragment thereof comprises CDRL1, CDRL2, and CDRL3 regions within a variable light chain amino acid sequence as set forth in SEQ ID NO: 7 and CDRH1, CDRH2 and CDRH3 regions within a variable heavy chain amino acid sequence as set forth in SEQ ID NO: 8; the transmembrane domain is from CD8α; the one or more co-stimulatory signaling domains is from CD137 (4-1BB); and the primary signaling domain is from CD3ζ.

### Claim 43 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)

The CAR of any one of claims 1 to 42, comprising an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to, or comprising SEQ ID NO: 9 or SEQ ID NO: 11.

### Claim 44 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)

The CAR of any one of claims 1 to 42, comprising an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to, or comprising any one of SEQ ID NOs: 49, 50, 51, 52, 61, 62, 63, 64, 73, 74, 75, 76, 85, 86, 87, 88, 97, 98, 99, 100, 109, 110, 111, 112, 121, 122, 123, 124, 125, 126, 135, 136, 137, 138, 147, 148, 149 or 150.

### Claim 45 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

A CAR that competes for binding to one or more epitopes of a human MUC16 polypeptide with the CAR of any one of claims 1 to 44.

### Claim 46 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45)

A polynucleotide encoding the CAR of any one of claims 1 to 45.

### Claim 47

A polynucleotide encoding a CAR, wherein the polynucleotide sequence encodes a polypeptide having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to, or comprises SEQ ID NO: 10 or SEQ ID NO: 12.

### Claim 48

A polynucleotide encoding a CAR, wherein the polynucleotide sequence encodes a polypeptide having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to, or comprising any one of SEQ ID NOs: 9, 11, 49, 50, 51, 52, 61, 62, 63, 64, 73, 74, 75, 76, 85, 86, 87, 88, 97, 98, 99, 100, 109, 110, 111, 112, 121, 122, 123, 124, 125, 126, 135, 136, 137, 138, 147, 148, 149 or 150.

### Claim 49 (depends on 46, 47, 48)

A vector comprising the polynucleotide of any one of claims 46-48.

### Claim 50 (depends on 49)

The vector of claim 49, wherein the vector is an expression vector.

### Claim 51 (depends on 49)

The vector of claim 49, wherein the vector is an episomal vector.

### Claim 52 (depends on 49)

The vector of claim 49, wherein the vector is a viral vector.

### Claim 53 (depends on 49)

The vector of claim 49, wherein the vector is a retroviral vector.

### Claim 54 (depends on 49)

The vector of claim 49, wherein the vector is a lentiviral vector.

### Claim 55 (depends on 49)

The vector of claim 49, wherein the vector is an adeno-associated viral vector.

### Claim 56 (depends on 54)

The vector of claim 54, wherein the lentiviral vector is selected from the group consisting of: human immunodeficiency virus 1 (HIV-1); human immunodeficiency virus 2 (HIV-2), visna-maedi virus (VMV) virus; caprine arthritis-encephalitis virus (CAEV); equine infectious anemia virus (EIAV); feline immunodeficiency virus (FIV); bovine immune deficiency virus (BIV); and simian immunodeficiency virus (SIV).

### Claim 57 (depends on 26, 27, 49, 50, 51, 52, 53, 54, 55, 56)

The vector according to any one of claims 49 to 56, comprising a left (5′) retroviral LTR, a Psi (Ψ) packaging signal, a central polypurine tract/DNA flap (cPPT/FLAP), a retroviral export element; a promoter operably linked to the polynucleotide of claim 26 or claim 27; and a right (3′) retroviral LTR.

### Claim 58 (depends on 57)

The vector of claim 57, further comprising a heterologous polyadenylation sequence.

### Claim 59 (depends on 58)

The vector of any of claim 58, wherein the promoter of the 5′ LTR is replaced with a heterologous promoter.

### Claim 60 (depends on 59)

The vector of claim 59, wherein the heterologous promoter is a cytomegalovirus (CMV) promoter, a Rous Sarcoma Virus (RSV) promoter, or an Simian Virus 40 (SV40) promoter.

### Claim 61 (depends on 57, 58, 59, 60)

The vector of any one of claims 57 to 60, wherein the 5′ LTR or 3′ LTR is a lentivirus LTR.

### Claim 62 (depends on 57, 58, 59, 60, 61)

The vector of any one of claims 57 to 61, wherein the 3′ LTR comprises one or more modifications.

### Claim 63 (depends on 57, 58, 59, 60, 61, 62)

The vector of any one of claims 57-62 wherein the 3′ LTR comprises one or more deletions.

### Claim 64 (depends on 57, 58, 59, 60, 61, 62, 63)

The vector of any one of claims 57 to 63, wherein the 3′ LTR is a self-inactivating (SIN) LTR.

### Claim 65 (depends on 47, 48, 57, 58, 59, 60, 61, 62, 63, 64)

The vector of any one of claims 57 to 64, wherein the promoter operably linked to the polynucleotide of any one of claims 47-48 is selected from the group consisting of: a cytomegalovirus immediate early gene promoter (CMV), an elongation factor 1 alpha promoter (EF1-α), a phosphoglycerate kinase-1 promoter (PGK), a ubiquitin-C promoter (UBQ-C), a cytomegalovirus enhancer/chicken beta-actin promoter (CAG), polyoma enhancer/herpes simplex thymidine kinase promoter (MC1), a beta actin promoter (β-ACT), a simian virus 40 promoter (SV40), and a myeloproliferative sarcoma virus enhancer, negative control region deleted, dl587rev primer-binding site substituted (MND) promoter.

### Claim 66 (depends on 46, 47, 48, 65)

The vector of claim 65, wherein the promoter operably linked to the polynucleotide of any one of claims 46-48 is an MND promoter.

### Claim 67 (depends on 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66)

A cell comprising the vector of any one of claims 49 to 66.

### Claim 68 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45)

A cell comprising the CAR of any one of claims 1-45.

### Claim 69 (depends on 67, 68)

The cell of claim 67 or 68, wherein the cell is an immune effector cell.

### Claim 70 (depends on 69)

The cell of claim 69, wherein the immune effector cell is a cytotoxic T lymphocytes (CTLs), a tumor infiltrating lymphocytes (TILs), or a helper T cell.

### Claim 71 (depends on 67, 68)

The cell of claim 67 or 68, wherein the cell is a T cell.

### Claim 72 (depends on 67, 68)

The cell of claim 67 or 68, wherein the cell is an αβ T cell, a γδ T cell, a natural killer (NK) cell, or a natural killer T (NKT) cell.

### Claim 73 (depends on 67, 68, 69, 70, 71, 72)

A composition comprising the cell of any one of claims 67 to 72.

### Claim 74 (depends on 67, 68, 69, 70, 71, 72)

A pharmaceutical composition comprising the cell of any one of claims 67 to 72 and a physiologically acceptable excipient.

### Claim 75 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66)

A method of generating an immune effector cell comprising a CAR according to any one of claims 1 to 45 comprising introducing into an immune effector cell the polynucleotide of any one of claims 46-48, or the vector of any one of claims 49-66.

### Claim 76 (depends on 73, 74)

A method of treating a cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the composition of claim 73 or the pharmaceutical composition of claim 74.

### Claim 77 (depends on 76)

The method of claim 76, wherein the cancer is a solid cancer, optionally wherein the solid cancer expresses MUC16.

### Claim 78 (depends on 77)

The method of claim 77, wherein the solid cancer is selected from the group consisting of sarcoma, prostate cancer, uterine cancer, thyroid cancer, testicular cancer, renal cancer, pancreatic cancer, ovarian cancer, cervical, mesothelioma, esophageal cancer, lung cancer, non-small-cell lung cancer, small cell lung cancer, melanoma, hepatocellular carcinoma, head and neck cancer, gastric cancer, endometrial cancer, fallopian tube cancer, colorectal cancer, cholangiocarcinoma, breast cancer, and bladder cancer.

### Claim 79 (depends on 77)

The method of claim 77, wherein the solid cancer is selected from the group consisting of ovarian, endometrial cancer, cervical cancer, mesothelioma, NSCLC, and SCLC.

### Claim 80 (depends on 77)

The method of claim 77, wherein the solid cancer is ovarian cancer.

### Claim 81 (depends on 76, 77, 78, 79, 80)

The method of any one of claims 76 to 80, wherein the composition is administered in combination with an additional therapeutic agent.

### Claim 82 (depends on 73, 74)

A method of treating a cancer in a subject who has received or is receiving a therapeutic agent, comprising administering to the subject a therapeutically effective amount of the composition of claim 73 or the pharmaceutical composition of claim 74.

### Claim 83 (depends on 81, 82)

The method of claim 81 or 82, wherein the composition and therapeutic agent are administered sequentially or simultaneously.

### Claim 84 (depends on 81, 82, 83)

The method of any one of claims 81 to 83, wherein the therapeutic agent is an immune checkpoint inhibitor, oncolytic virus, or co-stimulatory antibody.

### Claim 85 (depends on 84)

The method of claim 84, wherein the immune checkpoint inhibitor binds a checkpoint protein or corresponding ligand selected from the group consisting of: programmed cell death protein 1 (PD-1; PDCD1), lymphocyte activation gene 3 protein (LAG-3), T cell immunoglobulin domain and mucin domain protein 3 (TIM-3), cytotoxic T lymphocyte antigen-4 (CTLA-4), band T lymphocyte attenuator (BTLA), glucocorticoid-induced tumor necrosis factor receptor (GITR), T cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain (TIGIT), V-domain Ig suppressor of T cell activation (VISTA), killer cell immunoglobulin-like receptor (KIR), ICOS, ICOSL, OX40, B7-H3, B7-H4, CD47, 4-1BB, CD27, and CD70.

### Claim 86 (depends on 84, 85)

The method of claim 84 or 85, wherein the immune checkpoint inhibitor is a PD-1 inhibitor or PD-L1 inhibitor.

### Claim 87 (depends on 86)

The method of claim 86, wherein the PD-1 inhibitor or PD-L1 inhibitor is an anti-PD-1 or anti-PD-L1 antibody or antigen-binding fragment thereof.

### Claim 88 (depends on 87)

The method of claim 87, wherein the PD-1 inhibitor is selected from the group consisting of: nivolumab, pembrolizumab, atezolizumab, and cemiplimab.

### Claim 89 (depends on 84)

The method of claim 84, wherein the co-stimulatory antibody is a bi-specific antibody.

### Claim 90 (depends on 89)

The method of claim 89, wherein the bi-specific antibody binds a tumor associated antigen (TAA) and CD3.

### Claim 91 (depends on 89)

The method of claim 89, wherein the bi-specific antibody binds a TAA and CD28.

### Claim 92 (depends on 90, 91)

The method of claim 90 or claim 91, wherein the TAA is selected from the group consisting of AFP, ALK, BAGE proteins, β-catenin, brc-abl, BRCA1, BORIS, CA9, carbonic anhydrase IX, caspase-8, CCR5, CD40, CDK4, CEA, CTLA4, cyclin-B1, CYP1B1, ErbB3, ErbB4, ETV6-AML, Fra-1, FOLR1, GAGE proteins (e.g., GAGE-1, -2), GD2, GloboH, glypican-3, GM3, gp100, Her2, HLA/B-raf, HLA/k-ras, HLA/MAGE-A3, hTERT, LMP2, MART-1, ML-IAP, Muci, Muc2, Muc3, Muc4, Muc5, Muci6, MUM1, NA17, NY-BR1, NY-BR62, NY-BR85, OX40, p15, p53, PAP, PAX3, PAX5, PCTA-1, PRLR, RAGE proteins, Ras, RGS5, Rho, SART-1, SART-3, Steap-1, Steap-2, survivin, TGF-β, TMPRSS2, Tn, TRP-1, TRP-2, tyrosinase, uroplakin-3, alpha folate receptor (FRα), αvβ6 integrin, B cell maturation antigen (BCMA), B7-H3 (CD276), B7-H6, carbonic anhydrase IX (CAIX), CCR1, CD16, CD19, CD20, CD22, CD30, CD33, CD3γ, CD38, CD44, CD44v6, CD44v7/8, CD70, CD79a, CD79b, CD123, CD133, CD135 (also known as fmc like tyrosine kinase 3; FLT3), CD138, CD171, carcinoembryonic antigen (CEA), Claudin-6 (CLDN6), C-type lectin-like molecule-1 (CLL-1), CD2 subset 1 (CS-1), chondroitin sulfate proteoglycan 4 (CSPG4), cutaneous T cell lymphoma-associated antigen 1 (CTAGE1), epidermal growth factor receptor (EGFR), epidermal growth factor receptor variant III (EGFRvIII), epithelial glycoprotein 2 (EGP2), epithelial glycoprotein 40 (EGP40), epithelial cell adhesion molecule (EPCAM), ephrin type-A receptor 2 (EPHA2), fibroblast activation protein (FAP), Fc Receptor Like 5 (FCRL5), fetal acetylcholinesterase receptor (AchR), ganglioside G2 (GD2), ganglioside G3 (GD3), Glypican-3 (GPC3), EGFR family including ErbB2 (HER2), IL-11Rα, IL-13Rα2, Kappa, cancer/testis antigen 2 (LAGE-1A), Lambda, Lewis-Y (LeY), L1 cell adhesion molecule (L1-CAM), Leukocyte immunoglobulin-like receptor subfamily B member 2 (LILRB2); melanoma antigen gene (MAGE)-A1, MAGE-A3, MAGE-A4, MAGE-A6, MAGEA10, melanoma antigen recognized by T cells 1 (MelanA or MART1), Mesothelin (MSLN), neural cell adhesion molecule (NCAM), cancer/testis antigen 1 (NY-ESO-1), polysialic acid; placenta-specific 1 (PLAC1), preferentially expressed antigen in melanoma (PRAME), prostate stem cell antigen (PSCA), prostate-specific membrane antigen (PSMA), receptor tyrosine kinase-like orphan receptor 1 (ROR1), synovial sarcoma, X breakpoint 2 (SSX2), tumor associated glycoprotein 72 (TAG72), T-cell immunoglobulin and mucin-domain containing-3 (TIM-3), tumor endothelial marker 1 (TEM1/CD248), tumor endothelial marker 7-related (TEM7R), trophoblast glycoprotein (TPBG), NKG2D ligands, vascular endothelial growth factor receptor 2 (VEGFR2), and Wilms tumor 1 (WT-1).

### Claim 93 (depends on 90, 91)

The method of claim 90 or claim 91, wherein the TAA is MSLN.

### Claim 94 (depends on 90, 91)

The method of claim 90 or claim 91, wherein the TAA is alpha folate receptor (FRα).

### Claim 95 (depends on 90, 91)

The method of claim 90 or claim 91, wherein the TAA is MUC16.

### Claim 96 (depends on 81, 82, 83)

The method of any one of claims 81-83, wherein the therapeutic agent is a vascular endothelial growth factor (VEGF) inhibitor.

### Claim 97 (depends on 96)

The method of claim 96, wherein the VEGF inhibitor is bevacizumab.

### Claim 98 (depends on 81, 82, 83)

The method of any one of claims 81-83, wherein the therapeutic agent is a cytokine.

### Claim 99 (depends on 98)

The method of claim 98, wherein the cytokine is IL-2 or masked IL-2.

### Claim 100 (depends on 81, 82, 83)

The method of any one of claims 81-83, wherein the therapeutic agent is an oncolytic virus.

### Claim 101 (depends on 100)

The method of claim 100, wherein the oncolytic virus selected from the group consisting of VSV (Voyager V1), HSV, adenovirus, maraba virus, measles virus, NDV, picornavirus, reovirus, or vaccinia virus.

### Claim 102 (depends on 100)

The method of claim 100, wherein the oncolytic virus is Voyager V1.
